Medpace Holdings Inc (MEDP) Stock Price, Quote & News

Company Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical moni...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 513 579 9911

Fax: 513 579 0444

Website: www.medpace.com

Address:

5375 Medpace Way, Cincinnati, United States

BillionerOfKing Jan. 15 at 7:49 PM

$MEDP Current Stock Price: $612.46 Contracts to trade: $610 MEDP Jan 16 2026 Call Entry: $6.70 Exit: $11.73 ROI: 75% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

50bps Jan. 7 at 2:47 PM

$MEDP 👀

0 · Reply

SaraSheridan1075 Jan. 2 at 4:07 PM

$APG $IONQ $JLL $MEDP $BWXT Clear perspective again

0 · Reply

TrendDrivenAnalyst Dec. 27 at 7:15 AM

$MEDP Sentiment increasingly tracks operational truth rather than guidance tone. Competitive advantages must begin to appear in core metrics. Credible progress tends to compress risk premiums. Investors will likely insist on proof before expanding exposure.

0 · Reply

JarvisFlow Dec. 15 at 9:03 PM

Barclays updates rating for Medpace Hldgs ( $MEDP ) to Underweight, target set at 485 → 525.

0 · Reply

oakleighcastillo Dec. 12 at 5:44 PM

$MIGI $MEDP Mainz Biomed is calm on the tape, no panic, just absorption around $1.01–$1.02, and I like that the narrative has multiple legs with PancAlert flashing 100% sensitivity and 95% specificity as bonus optionality

0 · Reply

GoldenStripe Dec. 12 at 12:02 AM

$MEDP

0 · Reply

StoxWise369 Dec. 11 at 3:55 PM

$BEAT ♦️♦️♦️New Cardio AI controls! New comer for Cardio Market! IMO “HeartBeam and Samsung have a strategic partnership focused on improving at-home cardiac care, combining HeartBeam's advanced AI-driven VECG (Vector Electrocardiogram) tech with Samsung's popular Galaxy smartwatches…” $ISRG $MEDP $BSX

0 · Reply

AStrokeOfLuck Dec. 4 at 7:15 PM

$FTRE $CRL $ICLR $IQV $MEDP

0 · Reply

RonIsWrong Dec. 4 at 7:09 PM

$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV

0 · Reply

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026

Nov 27, 2025, 9:11 AM EST - 7 weeks ago

Wasatch Global Opportunities Fund Q3 2025 Contributors And Detractors

FOUR MOD

Nov 18, 2025, 12:59 PM EST - 2 months ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN GH WGS

Oct 24, 2025, 9:55 AM EDT - 3 months ago

Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings

Oct 23, 2025, 4:52 PM EDT - 3 months ago

Medpace: Full CRO Model Builds Net Revenue Growth, Maintain At Strong Buy

Oct 23, 2025, 1:37 PM EDT - 3 months ago

Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 12:00 PM EDT - 3 months ago

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Oct 23, 2025, 11:15 AM EDT - 3 months ago

Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back

Oct 22, 2025, 9:30 PM EDT - 3 months ago

Six Names, Six Narratives: Optimist Fund's Q3 Performance Map

CVNA FVRR TDUP W

Oct 22, 2025, 4:15 PM EDT - 3 months ago

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Sep 23, 2025, 4:05 PM EDT - 4 months ago

Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025

Sep 17, 2025, 5:14 AM EDT - 4 months ago

Medpace: Profit Margin, Growth, And Repurchase Program Will Trump Legislative Headwinds (Rating Upgrade)

Aug 4, 2025, 2:25 AM EDT - 5 months ago

Medpace: Return Of The Mack, With Double-Digit Revenue Growth

Jul 22, 2025, 2:14 PM EDT - 6 months ago

Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:00 PM EDT - 6 months ago

Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase

Jul 22, 2025, 7:36 AM EDT - 6 months ago

This Clinical Trials Stock Just Soared 40%. What Caused It to Pop.

Jul 22, 2025, 7:02 AM EDT - 6 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

RXRX

Jul 21, 2025, 4:15 PM EDT - 6 months ago

Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Jun 23, 2025, 4:05 PM EDT - 7 months ago

Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

Apr 22, 2025, 3:42 PM EDT - 9 months ago

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Apr 21, 2025, 4:15 PM EDT - 9 months ago

Medpace Holdings, Inc. Reports First Quarter 2025 Results

Apr 4, 2025, 8:14 AM EDT - 10 months ago

Medpace Holdings: It Might Be Time To Buy In

Mar 18, 2025, 4:05 PM EDT - 10 months ago

Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

Mar 1, 2025, 11:00 AM EST - 11 months ago

The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation

Feb 11, 2025, 5:40 PM EST - 1 year ago

Medpace Holdings, Inc. (MEDP) Q4 2024 Earnings Call Transcript

Feb 10, 2025, 4:15 PM EST - 1 year ago

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

Feb 5, 2025, 10:46 PM EST - 1 year ago

Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential

Feb 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Medpace Holdings, Inc. For Securities Fraud

Jan 30, 2025, 11:00 AM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Jan 28, 2025, 11:00 AM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 24, 2025, 2:35 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2025: Part 6

ALLY FTI OS PTON UAMY VRT

Jan 15, 2025, 1:15 PM EST - 1 year ago

Medpace Holdings Inc Is Being Investigated For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Jan 8, 2025, 11:15 AM EST - 1 year ago

Medpace Holdings Inc Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Jan 2, 2025, 4:05 PM EST - 1 year ago

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025

Jan 2, 2025, 11:15 AM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Dec 14, 2024, 5:15 PM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Dec 10, 2024, 5:30 PM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Dec 6, 2024, 6:00 PM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Contact The Schall Law Firm

Dec 4, 2024, 5:00 PM EST - 1 year ago

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

BillionerOfKing Jan. 15 at 7:49 PM

0 · Reply

50bps Jan. 7 at 2:47 PM

$MEDP 👀

0 · Reply

SaraSheridan1075 Jan. 2 at 4:07 PM

$APG $IONQ $JLL $MEDP $BWXT Clear perspective again

0 · Reply

TrendDrivenAnalyst Dec. 27 at 7:15 AM

0 · Reply

JarvisFlow Dec. 15 at 9:03 PM

Barclays updates rating for Medpace Hldgs ( $MEDP ) to Underweight, target set at 485 → 525.

0 · Reply

oakleighcastillo Dec. 12 at 5:44 PM

0 · Reply

GoldenStripe Dec. 12 at 12:02 AM

$MEDP

0 · Reply

StoxWise369 Dec. 11 at 3:55 PM

0 · Reply

AStrokeOfLuck Dec. 4 at 7:15 PM

$FTRE $CRL $ICLR $IQV $MEDP

0 · Reply

RonIsWrong Dec. 4 at 7:09 PM

0 · Reply

CatRocks Dec. 4 at 2:59 PM

$MEDP Back to $458?

0 · Reply

Zachary192 Dec. 2 at 1:59 PM

$MEDP doomed lol

0 · Reply

Zachary192 Dec. 2 at 1:59 PM

$MEDP

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:32 AM

$MDB $MDBX $MDXG $MEC $MEDP

0 · Reply

Zanetrades Nov. 30 at 8:40 PM

$MEDP Following a strong Q3 2025, one rating service upgraded MEDP to a “Strong Buy” under the framework of rising earnings estimates — suggesting near-term optimism on profit growth...

0 · Reply

Zanetrades Nov. 30 at 7:37 PM

$MEDP Several recent analyses highlight strong fundamentals: good revenue growth, a robust cash-flow profile, and an expanding pipeline of “net new business awards,” which suggests that demand for Medpace’s clinical-research services remains healthy.

0 · Reply

Zanetrades Nov. 30 at 7:36 PM

$MEDP Up 100% almost long term nice

0 · Reply

Zanetrades Nov. 30 at 7:35 PM

$MEDP

0 · Reply

StockConsultant Nov. 26 at 2:17 PM

$MEDP Medpace stock, watch for a narrow range breakout at https://stockconsultant.com/?MEDP

0 · Reply

BEATOFtheMARKET Nov. 25 at 8:17 PM

$MDB $MDBX $MDXG $MEC $MEDP

0 · Reply

MichaelKTrades Nov. 23 at 6:39 PM

A few biotech/medical names holding up with constructive price charts. $MEDP $PTGX $INCY (Pullback buy set up)

0 · Reply

WAJeff Nov. 23 at 6:00 PM

$MEDP Not pulling the trigger here was a total idiot moment. 85% since July 14 callout.

1 · Reply

Market Cap	17.36B
Revenue (ttm)	2.11B
Net Income (ttm)	404.39M
EPS (ttm)	N/A
PE Ratio	42.55
Forward PE	36.60
Profit Margin	19.17%
Debt to Equity Ratio	0.00

Volume	230,072
Avg Vol	241,458
Day's Range	N/A - N/A
Shares Out	28.17M
Stochastic %K	97%
Beta	1.43
Analysts	Hold
Price Target	$561.73